Although biotech is still somewhat of a young industry, and for the most part, not yet profitable, it has the technological resources and capabilities now to tackle the challenges of neglected diseases, said Christopher Earl, CEO of BIO Ventures for Global Health. (BioWorld Financial Watch)

Although biotechnology is still somewhat of a young industry, and for the most part, not yet profitable, it has the technological resources and capabilities now to tackle the challenges of neglected diseases, said Christopher Earl, CEO of BIO Ventures for Global Health. (BioWorld Financial Watch)

WASHINGTON - The biotech and pharmaceutical makers' support for getting a follow-on biologics bill passed this year is an attempt to "cut a deal" with Congress to secure at least 12 years of data exclusivity, said Kathleen Jaeger, CEO of the Generic Pharmaceutical Association (GPhA). (BioWorld Today)

WASHINGTON - The biotech and pharmaceutical makers' support for getting a follow-on biologics bill passed this year is an attempt to "cut a deal" with Congress to secure at least 12 years of data exclusivity, said Kathleen Jaeger, CEO of the Generic Pharmaceutical Association (GPhA). (BioWorld Today)